In silico drug discovery services market is likely to be worth USD 124 million by 2030}}{{>>
The report features an extensive study on the current landscape and the likely future potential of the companies offering services for the discovery of large molecule drugs based on the use of in silico tools and techniques. The study features an in-depth analysis, highlighting the capabilities of various industry stakeholders. In addition to other elements, the report includes:
A detailed assessment of the current market landscape of companies offering in silico drug discovery services for large molecules.
Elaborate profiles of key industry players that offer a wide range of in silico drug discovery services (shortlisted on the basis of the company size).
A detailed peer group-based benchmarking analysis, comparing the involved players based on several relevant parameters related to company and services.
An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain.
A detailed analysis assessing the current opportunity within in silico drug discovery services market.
A discussion on the various business strategies that can be adopted by in silico drug discovery service providers in order to maintain a competitive edge in this industry.
An insightful analysis highlighting the cost saving potential associated with the use of in silico approaches in the drug discovery process.
A case study comparing the key challenges associated with the discovery and production of large molecules.
Insights from an industry-wide survey, featuring inputs solicited from various experts in this domain.
A discussion on the upcoming computational approaches that are being adopted for drug discovery purposes.
A case study highlighting several non-computational methods / technologies used in drug discovery process.
- A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Key Drug Discovery Steps
Target Identification
Target Validation
Hit Generation
Hit-to-Lead
Lead Optimization
Type of Large Molecule
Antibodies
Proteins
Peptides
Nucleic Acids
Vectors
Company Size
Small
Mid-sized
Large
Target therapeutic Area
Autoimmune Disorders
Blood Disorders
Cardiovascular Disorders
Gastrointestinal and Digestive Disorders
Hormonal Disorders
Human Immunodeficiency Virus (HIV) / Acquired Immunodeficiency Syndrome (AIDS)
Infectious Diseases
Metabolic Disorders
Mental Disorders
Musculoskeletal Disorders
Neurological Disorders
Oncological Disorders
Respiratory Disorders
Skin Disorders
Urogenital Disorders
Others
Type of Sponsor
Industry Players
Non-Industry Players
Key Geographical Regions
North America
Europe
Asia-Pacific
- Transcripts of interviews held with the following senior level representatives of stakeholder companies
- John L Kulp (Chief Executive Officer and Chief Technical Officer, Conifer Point Pharmaceuticals)
- Sven Benson (Founder, candidum)
- Mark Whittaker (Senior Vice President, Evotec)
- Edelmiro Moman (Scientific Consultant and Teacher, ProSciens)
Abzena
BioDuro
BioNTech
ChemPartner
Creative Biostructure
GenScript
LakePharma
Sundia MediTech
Sygnature Discovery
Viva Biotech
https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html
Other Recent Offerings
- DNA-Encoded Libraries: Platforms and Services Market
- Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030
- Companion Diagnostics Services Market, 2020-2030
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]
No comments yet... Be the first to leave a reply! Login here